Tags : Develop

Biosimilars

Cipla Collaborates with Kemwell to Form Joint Venture to Develop

Shots: The companies collaborated to form JV to develop, manufacture, and commercialize biosimilars for a global market The collaboration will utilize Cipla and Kemwell’s strengths for product development, clinical development, regulatory filings, manufacturing, and commercialization of biopharma products Cipla’s respiratory expertise & Kemwell’s biologics will combine to accelerate the products in the market Click here […]Read More

Biotech

Orion Signs a License and Research Agreement with Alligator to

Shots: Alligator to receive up front & research support payments. If Orion exercises its options to continue the development and commercialization of the product then Alligator will be further eligible to receive $548.41M as development, approval, and sales milestone for all three product candidates along with royalties The focus of the collaboration is to discover […]Read More

Biotech

Seagen Signs an Exclusive WW License Agreement with RemeGen to

Shots: RemeGen to receive $200M up front for development and commercialization rights of disitamab vedotin outside of Remegen’s territory & ~$2.4B upon the achievement of milestones across multiple indications along with royalties on sales of the therapy in Seagen’s territory RemeGen will retain development & commercialization rights of the therapy in Asia (Ex-Japan & Singapore). […]Read More

Pharma

AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies

Shots: The companies collaborated to research, develop & commercialize small molecules directed against the GPR75 target with the potential to treat obesity and related co-morbidities The collaboration builds on the findings from the Regeneron Genetics Center of rare genetic mutations in the GPR75 gene associated with protection against obesity and on early joint research initiated […]Read More

Biotech

Skyhawk Collaborate with Aragen to Develop Novel Small Molecule Therapeutics

Shots: Skyhawk collaborated with Aragen for the development of small molecule therapeutics that correct RNA expression Under the collaboration, Skyhawk will get multiple discovery chemistry and biology service solutions from Aragen The alliance focuses to accelerate Skyhawk’s research pipeline. Aragen’s research expertise will help Skyhawk to advance the development of its novel small molecule therapeutics […]Read More

Biotech

Arrowhead Signs a License Agreement with Horizon to Develop siRNA

Shots: Arrowhead to receive $40M up front and is eligible to receive ~$660M as potential development, regulatory & commercial milestones, and is further eligible to receive royalties on net product sales Horizon to receive a WW exclusive license for ARO-XDH targeting XDH and will be wholly responsible for clinical development and commercialization of the therapy […]Read More

Biotech

Kite Enter into a Partnership with Shoreline Biosciences to Develop

Shots: Shoreline is eligible to receive ~$2.3B including upfront, development and commercialization milestones and additional payments along with royalties. The agreement follows Kite’s investment in Shoreline’s recent Series A financing The collaboration will utilize Shoreline’s iPSC differentiation and genetic reprogramming with Kite’s cell therapy to develop novel allogeneic therapies for hematologic malignancies Initially, the collaboration […]Read More